The most recent example of this ray of hope is the agencyâ€™s championing of adaptive clinical trials. "Traditional" clinical trials that demonstrate a 40% efficacy rate without even attempting to isolate which 40% is expensive in financial terms and only marginally helpful in helping physicians best treat their patients. It also plays into the hands of the Evangelists of Evidence-based Medicine and the Votaries of Me-Tooism. We must think about clinical trials in new ways. It's a crucial aspect of the Critical Path.
Yesterday, Deputy Commissioner Dr. Scott Gottlieb made such a point at a Manhattan Institute talk â€“ and it sure was refreshing.
Scottâ€™s full remarks can be found by clicking the link below: